Literature DB >> 10784378

Urinary hypoxanthine and xanthine levels in acute coronary syndromes.

N Turgan1, B Boydak, S Habif, C Gülter, B Senol, I Mutaf, D Ozmen, O Bayindir.   

Abstract

Ischemia leads to impaired ATP metabolism, with increased production of purine degradation products, such as hypoxanthine and xanthine, which are useful markers of tissue hypoxia. These extracellular markers of ischemia have been studied extensively in many clinical conditions of oxidative stress, including perinatal asphyxia, acute respiratory distress syndrome, cerebral ischemia, and preeclampsia. The aim of this study was to explore the usefulness of urinary hypoxanthine and xanthine as ischemia markers in acute coronary syndromes. Urinary excretion of hypoxanthine and xanthine was assessed by high-performance liquid chromatography in 30 patients with acute coronary syndromes and in 30 age- and sex-matched controls. Serum and urine uric acid, creatinine, and urea concentrations were also determined. Hypoxanthine excretion was significantly elevated in patients compared with healthy controls (84.37+/-8.63 and 42.70+/-3.97 nmol/mg creatinine, mean+/-SEM, P<0.0001). Urinary xanthine levels were also increased in patients with acute coronary syndromes (100.13+/-12.14 and 34.74+/-4.07 nmol/mg creatinine patients and controls, respectively; P<0.0001). Hypoxanthine and xanthine excretion showed a strong positive correlation in both groups. Significant negative correlations between urinary hypoxanthine and uric acid and xanthine and uric acid were observed in the patients, but not in controls. In conclusion, increased levels of ATP degradation products hypoxanthine and xanthine are observed in various hypoxic clinical conditions. This study suggests that these parameters may be useful markers of ischemia in patients with acute coronary syndromes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10784378     DOI: 10.1007/s005990050084

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  8 in total

1.  A new data mining approach for profiling and categorizing kinetic patterns of metabolic biomarkers after myocardial injury.

Authors:  Christian Baumgartner; Gregory D Lewis; Michael Netzer; Bernhard Pfeifer; Robert E Gerszten
Journal:  Bioinformatics       Date:  2010-05-18       Impact factor: 6.937

2.  Cell-free plasma DNA and purine nucleotide degradation markers following weightlifting exercise.

Authors:  Johanna Atamaniuk; Claudia Vidotto; Markus Kinzlbauer; Norbert Bachl; Beate Tiran; Harald Tschan
Journal:  Eur J Appl Physiol       Date:  2010-06-26       Impact factor: 3.078

3.  Assessment of uric acid and lipid peroxidation in serum and urine after hypoxia-ischemia neonatal in rats.

Authors:  V C Pimentel; F V Pinheiro; M Kaefer; R N Moresco; M B Moretto
Journal:  Neurol Sci       Date:  2010-08-21       Impact factor: 3.307

4.  The Metabolomic Characterization of Different Types of Coronary Atherosclerotic Heart Disease in Male.

Authors:  Yuxuan Fan; Xianglan Quan; Shengquan Liu; Le Yue; Jizong Jiang; Zhiqing Fan
Journal:  Cardiol Res Pract       Date:  2022-07-12       Impact factor: 1.990

5.  Opioid use affects antioxidant activity and purine metabolism: preliminary results.

Authors:  Paolo Mannelli; Ashwin Patkar; Steve Rozen; Wayne Matson; Ranga Krishnan; Rima Kaddurah-Daouk
Journal:  Hum Psychopharmacol       Date:  2009-12       Impact factor: 1.672

6.  Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury.

Authors:  Gregory D Lewis; Ru Wei; Emerson Liu; Elaine Yang; Xu Shi; Maryann Martinovic; Laurie Farrell; Aarti Asnani; Marcoli Cyrille; Arvind Ramanathan; Oded Shaham; Gabriel Berriz; Patricia A Lowry; Igor F Palacios; Murat Taşan; Frederick P Roth; Jiangyong Min; Christian Baumgartner; Hasmik Keshishian; Terri Addona; Vamsi K Mootha; Anthony Rosenzweig; Steven A Carr; Michael A Fifer; Marc S Sabatine; Robert E Gerszten
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 7.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.

Authors:  Cristine E Berry; Joshua M Hare
Journal:  J Physiol       Date:  2003-12-23       Impact factor: 5.182

8.  Plasma level of hypoxanthine/xanthine as markers of oxidative stress with different stages of obstructive sleep apnea syndrome.

Authors:  Harmanjit S Hira; Pryanka Samal; Amandeep Kaur; Seema Kapoor
Journal:  Ann Saudi Med       Date:  2014 Jul-Aug       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.